New radiation approach for locally advanced lung cancer
Part of Lungs & breathing clinical trials.
This study tests a new way of giving radiation for people with locally advanced non-small cell lung cancer (NSCLC), along with a chemotherapy medicine (navelbine). It may help by improving how well the treatment controls the cancer in the chest while watching for side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed non-small cell lung cancer that has not spread far (stage IIB to IIIB).
- Your energy/function level is good (performance status 0 to 1).
- You can follow the treatment plan, visits, and follow-up schedule.
- You can safely receive the planned radiation dose (66 Gy over 33 sessions) and the treatment area’s normal tissues can be kept within safety limits.
- If you can become pregnant, you must have a negative pregnancy test; nursing/breastfeeding women cannot join.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests whether a specific kind of radiation can be safely given to people with newly diagnosed metastatic lung cancer when cure isn’t possible. It’s meant to see how well the treatment can be delivered and how it affects outcomes in a specific genetic group of tumors.
This trial tests whether adding a high, focused dose of radiation to the usual first treatment (chemo and/or immunotherapy) can help people with non-small cell lung cancer that has spread to a limited number of spots (up to 5). The goal is to see if this approach improves how well the treatment works.
This trial tests a new approach for advanced non-small cell lung cancer that cannot be surgically removed. It combines a focused, high-dose radiation treatment to the tumor core followed by standard chemotherapy and radiation together. This may help fight the cancer more effectively.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests whether a special type of focused radiation therapy can effectively treat advanced non-small cell lung cancer (the most common type) as an upfront treatment. It may help patients avoid or delay chemotherapy while controlling their cancer.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.